Advisory Services
Five integrated service lines spanning the innovation-to-commercialization lifecycle. Each engagement is bespoke, led by founding principals, and designed to eliminate the strategic fragmentation that slows biological technologies from reaching market.
BEACHHEAD OFFERINGS
Regulatory–Commercial Architecture Design
The primary entry point for most engagements. We design integrated regulatory pathways aligned with your commercialization roadmap and capital strategy, because a regulatory plan built without commercial context is a plan built to be revised.
Typical deliverables include:
- Jurisdiction sequencing roadmap
- Classification risk assessment
- Regulatory timeline modeling
- Product design constraints analysis
- Investor-facing regulatory narrative framing
Strategic Expansion & Portfolio War-Gaming
For growth-stage biological companies navigating multi-jurisdiction expansion and portfolio prioritization decisions. We stress-test your expansion strategy against regulatory bottlenecks, capital constraints, and competitive dynamics before you commit resources.
Typical deliverables include:
- Cross-jurisdiction expansion strategy
- Regulatory bottleneck forecasting
- Capital allocation alignment analysis
- Portfolio risk assessment and prioritization
- Commercialization sequencing
FOLLOW-ON OFFERINGS
Scientific & Product Development Governance Advisory
Senior-level advisory on the design and governance of R&D programs. We bring the discipline of decades of agricultural and biological product development leadership to companies building their development infrastructure for the first time, or rebuilding it after outgrowing their initial approach.
Focus areas include:
- R&D program design and stage-gate governance
- Data package strategy and development prioritization
- Portfolio management and resource allocation
- Development risk assessment
Fractional C-Suite Engagements
Selective fractional executive roles for companies requiring senior strategic leadership without full-time executive overhead. These engagements are high-touch and capacity-limited. We accept them based on strategic fit, not availability.
Roles include:
- Fractional Chief Commercial Officer
- Fractional Chief Development Officer
- Strategic Advisor to CEO
Investor Regulatory & Development Risk Audit
Independent regulatory, scientific, and portfolio diligence for investors evaluating frontier biological assets. We provide the domain-specific depth that general-purpose diligence providers cannot, because the risk in biological technologies lives in the details of regulatory classification, data package sufficiency, and development timeline credibility.
Concentrated Expertise
Our advisory work spans the full ag-bio product lifecycle. Within that scope, our practice is most concentrated in five biological-technology categories where regulatory complexity, commercialization risk, and market timing intersect most acutely: RNAi & dsRNA, gene-edited traits, peptide-based bioactives, novel mode-of-action biopesticides, and next-generation biostimulants.
Not sure which service line fits?
Most engagements begin with a scoping conversation. We’ll define the strategic problem together and determine where integrated advisory adds the most value.